Pharmanutra (PHN) Corporate presentation summary

Corporate structure and global presence

• Operates globally with subsidiaries in the USA and Spain, and acquired Akern for R&D in bioimpedance devices.

• Presence in 81 countries through 53 international partners.

• Expanded product distribution in China via cross-border e-commerce and digital platforms.

Product portfolio and innovation

• Main product families include SiderAL, Apportal, Cetilar, UltraMag, and Sidevit, covering nutraceuticals and medical devices.

• Four new products launched in September 2026, including Sucrosomial Creatine; three more and a new line planned for 2027.

• Sucrosomial technology applied to iron, vitamins, and minerals, offering higher absorption and effectiveness.

Financial performance and market growth

• Domestic H1 2026 revenues grew 9.3%, with increasing contributions from Akern and Cetilar Nutrition.

• Sell-out volumes up 11% year-on-year across all channels in H1 2026.

• Outperformed the Italian market in all product categories, with strong growth in SiderAL, Cetilar, and Apportal lines.